Semaphorin 3C As a Therapeutic Target in Prostate and Other Cancers

Overview

Journal Int J Mol Sci

Publisher MDPI

Specialties Biochemistry
Chemistry
Molecular Biology

Date 2019 Feb 15

PMID 30759745

Citations 16

Authors

Daniel H F Hui

Kevin J Tam

Ivy Z F Jiao

Christopher J Ong

Affiliations

Soon will be listed here.

Abstract

The semaphorins represent a large family of signaling molecules with crucial roles in neuronal and cardiac development. While normal semaphorin function pertains largely to development, their involvement in malignancy is becoming increasingly evident. One member, Semaphorin 3C (SEMA3C), has been shown to drive a number of oncogenic programs, correlate inversely with cancer prognosis, and promote the progression of multiple different cancer types. This report surveys the body of knowledge surrounding SEMA3C as a therapeutic target in cancer. In particular, we summarize SEMA3C's role as an autocrine andromedin in prostate cancer growth and survival and provide an overview of other cancer types that SEMA3C has been implicated in including pancreas, brain, breast, and stomach. We also propose molecular strategies that could potentially be deployed against SEMA3C as anticancer agents such as biologics, small molecules, monoclonal antibodies and antisense oligonucleotides. Finally, we discuss important considerations for the inhibition of SEMA3C as a cancer therapeutic agent.

Citing Articles

Downregulation of semaphorin 4A in keratinocytes reflects the features of non-lesional psoriasis.

Kume M, Koguchi-Yoshioka H, Nakai S, Matsumura Y, Tanemura A, Yokoi K Elife. 2024; 13.

PMID: 39737847 PMC: 11687936. DOI: 10.7554/eLife.97654.

Construction and validation of a prognostic signature based on microvascular invasion and immune-related genes in hepatocellular carcinoma.

Li H, Qiao L, Kong M, Fang H, Yan Z, Guo R Sci Rep. 2024; 14(1):26994.

PMID: 39506070 PMC: 11541849. DOI: 10.1038/s41598-024-78467-3.

A Pilot Study of the Role of Semaphorin 4A (sema4A) and 3C (sema3C) in Non-Muscle-Invasive Bladder Cancer (NMIBC).

Purpurowicz P, Kaminski T, Kordan W, Korzekwa A, Purpurowicz Z, Jablonowski Z Biomedicines. 2024; 12(10).

PMID: 39457718 PMC: 11504222. DOI: 10.3390/biomedicines12102407.

Semaphorins and Their Roles in Breast Cancer: Implications for Therapy Resistance.

Aiyappa-Maudsley R, McLoughlin L, Hughes T Int J Mol Sci. 2023; 24(17).

PMID: 37685898 PMC: 10487980. DOI: 10.3390/ijms241713093.

Perineural invasion in colorectal cancer: mechanisms of action and clinical relevance.

Wang H, Huo R, He K, Cheng L, Zhang S, Yu M Cell Oncol (Dordr). 2023; 47(1):1-17.

PMID: 37610689 PMC: 10899381. DOI: 10.1007/s13402-023-00857-y.

References

Li K, Chen M, Li L, Lu M, Shao C, Su Z . The predictive value of semaphorins 3 expression in biopsies for biochemical recurrence of patients with low- and intermediate-risk prostate cancer. Neoplasma. 2013; 60(6):683-9. DOI: 10.4149/neo_2013_087. View

Bao S, Wu Q, McLendon R, Hao Y, Shi Q, Hjelmeland A . Glioma stem cells promote radioresistance by preferential activation of the DNA damage response. Nature. 2006; 444(7120):756-60. DOI: 10.1038/nature05236. View

Esselens C, Malapeira J, Colome N, Casal C, Rodriguez-Manzaneque J, Canals F . The cleavage of semaphorin 3C induced by ADAMTS1 promotes cell migration. J Biol Chem. 2009; 285(4):2463-73. PMC: 2807303. DOI: 10.1074/jbc.M109.055129. View

Toyofuku T, Yoshida J, Sugimoto T, Yamamoto M, Makino N, Takamatsu H . Repulsive and attractive semaphorins cooperate to direct the navigation of cardiac neural crest cells. Dev Biol. 2008; 321(1):251-62. DOI: 10.1016/j.ydbio.2008.06.028. View

Wang Y, He H, Srivastava N, Vikarunnessa S, Chen Y, Jiang J . Plexins are GTPase-activating proteins for Rap and are activated by induced dimerization. Sci Signal. 2012; 5(207):ra6. PMC: 3413289. DOI: 10.1126/scisignal.2002636. View

Adams R, Lohrum M, Klostermann A, Betz H, Puschel A . The chemorepulsive activity of secreted semaphorins is regulated by furin-dependent proteolytic processing. EMBO J. 1997; 16(20):6077-86. PMC: 1326291. DOI: 10.1093/emboj/16.20.6077. View

Chen J, Li Y, Yu T, McKay R, Burns D, Kernie S . A restricted cell population propagates glioblastoma growth after chemotherapy. Nature. 2012; 488(7412):522-6. PMC: 3427400. DOI: 10.1038/nature11287. View

Song H, Zhu J, Lu D . Molecular-targeted first-line therapy for advanced gastric cancer. Cochrane Database Syst Rev. 2016; 7:CD011461. PMC: 6457914. DOI: 10.1002/14651858.CD011461.pub2. View

Zheng T, Menard M, Weiss W . Neuroblastoma Metastases: Leveraging the Avian Neural Crest. Cancer Cell. 2017; 32(4):395-397. PMC: 6209114. DOI: 10.1016/j.ccell.2017.09.012. View

10.

Solit D, Rosen N . Targeting HER2 in prostate cancer: where to next?. J Clin Oncol. 2007; 25(3):241-3. DOI: 10.1200/JCO.2006.08.8187. View

11.

Gunadi , Makhmudi A, Agustriani N, Rochadi . Effects of SEMA3 polymorphisms in Hirschsprung disease patients. Pediatr Surg Int. 2016; 32(11):1025-1028. DOI: 10.1007/s00383-016-3953-7. View

12.

Smolkin T, Nir-Zvi I, Duvshani N, Mumblat Y, Kessler O, Neufeld G . Complexes of plexin-A4 and plexin-D1 convey semaphorin-3C signals to induce cytoskeletal collapse in the absence of neuropilins. J Cell Sci. 2018; 131(9). DOI: 10.1242/jcs.208298. View

13.

Rehman M, Tamagnone L . Semaphorins in cancer: biological mechanisms and therapeutic approaches. Semin Cell Dev Biol. 2012; 24(3):179-89. DOI: 10.1016/j.semcdb.2012.10.005. View

14.

Luo Y, Raible D, Raper J . Collapsin: a protein in brain that induces the collapse and paralysis of neuronal growth cones. Cell. 1993; 75(2):217-27. DOI: 10.1016/0092-8674(93)80064-l. View

15.

Mire E, Hocine M, Bazellieres E, Jungas T, Davy A, Chauvet S . Developmental Upregulation of Ephrin-B1 Silences Sema3C/Neuropilin-1 Signaling during Post-crossing Navigation of Corpus Callosum Axons. Curr Biol. 2018; 28(11):1768-1782.e4. DOI: 10.1016/j.cub.2018.04.026. View

16.

Ji S, Qin Y, Shi S, Liu X, Hu H, Zhou H . ERK kinase phosphorylates and destabilizes the tumor suppressor FBW7 in pancreatic cancer. Cell Res. 2015; 25(5):561-73. PMC: 4423074. DOI: 10.1038/cr.2015.30. View

17.

Worzfeld T, Offermanns S . Semaphorins and plexins as therapeutic targets. Nat Rev Drug Discov. 2014; 13(8):603-21. DOI: 10.1038/nrd4337. View

18.

Ferlay J, Soerjomataram I, Dikshit R, Eser S, Mathers C, Rebelo M . Cancer incidence and mortality worldwide: sources, methods and major patterns in GLOBOCAN 2012. Int J Cancer. 2014; 136(5):E359-86. DOI: 10.1002/ijc.29210. View

19.

Neufeld G, Shraga-Heled N, Lange T, Guttmann-Raviv N, Herzog Y, Kessler O . Semaphorins in cancer. Front Biosci. 2004; 10:751-60. DOI: 10.2741/1569. View

20.

Sharma A, LeVaillant C, Plant G, Harvey A . Changes in expression of Class 3 Semaphorins and their receptors during development of the rat retina and superior colliculus. BMC Dev Biol. 2014; 14:34. PMC: 4121511. DOI: 10.1186/s12861-014-0034-9. View